BioPharma Credit PLC Notice of AGM (5775P)
May 29 2018 - 11:10AM
UK Regulatory
TIDMBPCR
RNS Number : 5775P
BioPharma Credit PLC
29 May 2018
29 MAY 2018
BioPharma Credit plc
(the "Company")
NOTICE OF ANNUAL GENERAL MEETING
INCLUDING A RECOMMENDED PROPOSAL
FOR THE APPROVAL OF A RELATED PARTY TRANSACTION
Following the publication on 7 March 2018 of its Annual
Financial Report for the year ended 31 December 2017, the Company
announces that it will hold its Annual General Meeting ("AGM") at
11 a.m. on 29 June 2018 at the offices of Herbert Smith Freehills
LLP, Exchange House, Primrose Street, London EC2A 2EG.
Alongside the ordinary business to be considered at the AGM and
as disclosed in the prospectus related to the Company's C Share
issue dated 14 March 2018, the Company is seeking shareholders'
approval of a related party transaction in respect of the amendment
to the Investment Management Agreement.
A copy of the Notice of the AGM is available to view on the
Company's website at http://www.bpcruk.com. It has also been
submitted to the National Storage Mechanism and will shortly be
available for inspection at www.morningstar.co.uk/NSM.
Copies of the Notice of the AGM, together with a form of proxy
for use in connection with the AGM, are being posted or made
available to the Company's Shareholders today.
Capitalised terms used in this announcement and not otherwise
defined will have the meanings given to them in the Notice of
AGM.
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27th
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOASEUFLUFASEDI
(END) Dow Jones Newswires
May 29, 2018 11:10 ET (15:10 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2023 to May 2024